Advanced Search

Technical Analysis for BLU - BELLUS Health Inc.

Grade Last Price % Change Price Change
C 4.4 -2.65% -0.12
BLU closed down 2.65 percent on Thursday, April 22, 2021, on 80 percent of normal volume.
Earnings due: May 12
*** please verify all earnings dates ***
12 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical BLU trend table...
Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Cup with Handle Other 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Stochastic Sell Signal Bearish -2.65%
Inside Day Range Contraction -2.65%
Wide Bands Range Expansion -2.65%
Overbought Stochastic Strength -2.65%
Wide Bands Range Expansion -0.23%
Overbought Stochastic Strength -0.23%
Older End-of-Day Signals for BLU ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 4 hours ago
Outside Day about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago
60 Minute Opening Range Breakdown about 6 hours ago
Down 3% about 6 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators Basic chart:

Profile

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Biology Alzheimer's Disease Specialty Drugs Abdominal Pain Cough Mozy Angiotensin Converting Enzyme Chronic Cough

Is BLU a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Apr 22 The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLU, EBIX and GOEV
Apr 22 The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLU, NEPT and RMO
Apr 21 The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BLU, SOS and NEPT
Apr 21 CLASS ACTION UPDATE for BLU, REGI and NEPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Apr 21 BLU NOTICE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against BELLUS Health, Inc.- BLU
Apr 21 The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLU, REGI and KDMN
Apr 20 10 Best Biotech Stocks Under $6 in 2021
Apr 20 The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BLU, XL and DDD
Apr 20 ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BELLUS Health Inc. Investors with Losses to Secure Counsel Before Important May 17 Deadline in Securities Class Action – BLU
Apr 19 Lawsuits Filed Against BLU, XL and VRM - Jakubowitz Law Pursues Shareholders Claims
See more BLU news...

Indicators

Indicator Value
52 Week High 12.03
52 Week Low 2.01
Average Volume 1,358,786
200-Day Moving Average 3.10
50-Day Moving Average 4.09
20-Day Moving Average 4.19
10-Day Moving Average 4.47
Average True Range 0.28
ADX 15.39
+DI 16.82
-DI 18.71
Chandelier Exit (Long, 3 ATRs ) 3.88
Chandelier Exit (Short, 3 ATRs ) 4.36
Upper Bollinger Band 4.83
Lower Bollinger Band 3.56
Percent B (%b) 0.66
BandWidth 30.17
MACD Line 0.14
MACD Signal Line 0.12
MACD Histogram 0.0175
Fundamentals Value
Market Cap 344.68 Million
Num Shares 78.3 Million
EPS -0.51
Price-to-Earnings (P/E) Ratio -8.65
Price-to-Sales 9686.31
Price-to-Book 2.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.87
Resistance 3 (R3) 4.87 4.73 4.79
Resistance 2 (R2) 4.73 4.61 4.72 4.76
Resistance 1 (R1) 4.56 4.54 4.49 4.56 4.74
Pivot Point 4.42 4.42 4.38 4.41 4.42
Support 1 (S1) 4.25 4.30 4.18 4.25 4.06
Support 2 (S2) 4.11 4.23 4.10 4.04
Support 3 (S3) 3.94 4.11 4.01
Support 4 (S4) 3.94